Plasma-derived versus recombinant factor concentrates in PUPs : A never ending debate?
Inhibitor development in haemophilia is a serious complication to treatment with factor concentrates. Since the advent of more pure products, especially developed using recombinant DNA technology, some studies have shown an increased incidence of inhibitors in previously untreated patients (PUPs) receiving recombinant products whereas plasmaderived concentrates sometimes have been claimed to have